FDG-PET AND PET/CT - Part I

Abstract Positron emission tomography (PET) with 18 F fluoro-deoxyglucose (FDG) is now an established functional imaging modality predominantly used in the work-up of several neoplastic diseases. It also has several neurological and cardiac applications in routine clinical practice. However, the radiopharmaceutical, 18 F-FDG, most commonly used for clinical PET studies today is also taken up by inflammatory and infectious cells and it also has a potential role in inflammation imaging in the future. Since this technique provides a map of glucose metabolism in the body, it is extremely important to understand the bio-distribution of FDG in the human body and factors that alter it. Accordingly, the technique used and several patient factors have a significant impact on the quality of images obtained. Hence, it becomes critical to perform this highly sophisticated exam with adequate patient preparation, following an accepted technique and interpret the images with the knowledge of normal and physiologic bio-distribution of FDG in several body organs and tissues. With this objective, this two-series review article will review the current principles and practice of clinical FDG-PET. The first section of this article deals mostly with basic aspects of FDG-PET and PET/CT including properties of FDG, PET instrumentation and technique and normal variants.

[1]  A. Alavi,et al.  Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer? , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  D. Lilien,et al.  Intense FDG activity in peritoneal tuberculosis mimics peritoneal carcinomatosis. , 2007, Clinical nuclear medicine.

[3]  A. Alavi,et al.  Dual-Time Point FDG PET Imaging in the Evaluation of Pulmonary Nodules With Minimally Increased Metabolic Activity , 2007, Clinical nuclear medicine.

[4]  Y Ishida,et al.  Benign variations and incidental abnormalities of myocardial FDG uptake in the fasting state as encountered during routine oncology positron emission tomography studies. , 2007, The British journal of radiology.

[5]  Abass Alavi,et al.  Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  R. Wahl,et al.  Lymphadenopathy Resulting From Acute Hepatitis C Infection Mimicking Metastatic Breast Carcinoma on FDG PET/CT , 2006, Clinical nuclear medicine.

[7]  Abass Alavi,et al.  Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  A. Alavi,et al.  Intense esophageal FDG activity caused by Candida infection obscured the concurrent primary esophageal cancer on PET imaging. , 2005, Clinical nuclear medicine.

[9]  M. Graham,et al.  Positron emission tomography/computed tomography imaging of head and neck tumors: an atlas. , 2005, Seminars in nuclear medicine.

[10]  Tsai Yuh-Feng,et al.  FDG PET CT features of an intraabdominal gossypiboma. , 2005, Clinical nuclear medicine.

[11]  E. Broussard,et al.  F-18 FDG PET-CT imaging of a mycotic aneurysm. , 2005, Clinical nuclear medicine.

[12]  Q. Le,et al.  Positron‐Emission Tomography for Surveillance of Head and Neck Cancer , 2005, The Laryngoscope.

[13]  C. Nathan,et al.  Unilateral Vocal Cord Paralysis Causes Contralateral False-Positive Positron Emission Tomography Scans of the Larynx , 2005, The Annals of otology, rhinology, and laryngology.

[14]  L. Weih,et al.  Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer , 2005, Head & neck.

[15]  Z. Gülbaş,et al.  Intense F-18 FDG accumulation in stomach in a patient with Hodgkin lymphoma: Helicobacter pylori infection as a pitfall in oncologic diagnosis with F-18 FDG PET imaging. , 2005, Clinical nuclear medicine.

[16]  F. Atkins,et al.  Reduction of Brown Fat 2-Deoxy-2-[F-18]fluoro-d-glucose Uptake by Controlling Environmental Temperature Prior to Positron Emission Tomography Scan , 2005, Molecular Imaging and Biology.

[17]  E. Kramer,et al.  Spectrum of thymic uptake at 18F-FDG PET. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.

[18]  J. Thie.  Understanding the standardized uptake value, its methods, and implications for usage. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  A. Alavi,et al.  Iatrogenic Artifacts on Whole-Body F-18 FDG PET Imaging , 2004, Clinical nuclear medicine.

[20]  R. Wahl,et al.  Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  G. V. von Schulthess,et al.  Positron emission tomography in the early follow-up of advanced head and neck cancer. , 2004, Archives of otolaryngology--head & neck surgery.

[22]  J. Talbot,et al.  Peritoneal tuberculosis revealed by carcinomatosis on CT scan and uptake at FDG‐PET , 2003, BJOG : an international journal of obstetrics and gynaecology.

[23]  Mithat Gonen,et al.  Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  W. Oyen,et al.  FDG-PET in infectious and inflammatory disease , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  Richard L Wahl,et al.  "USA-Fat": prevalence is related to ambient outdoor temperature-evaluation with 18F-FDG PET/CT. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  A. Lammertsma,et al.  The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[27]  M. Lobrano,et al.  Positron emission tomography in oncology. , 2003, Clinical journal of oncology nursing.

[28]  Val J Lowe,et al.  Clinical 18F-FDG oncology patient preparation techniques. , 2003, Journal of nuclear medicine technology.

[29]  Richard L Wahl,et al.  Uptake in supraclavicular area fat ("USA-Fat"): description on 18F-FDG PET/CT. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  Thomas F Hany,et al.  Positron emission tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in benign lesions, and in changes resulting from treatment. , 2002, AJR. American journal of roentgenology.

[31]  Abass Alavi,et al.  Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  R. D'Agostino,et al.  Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer , 2001, Head & neck.

[33]  D. Binns,et al.  Pattern of uptake and excretion of (18)F-FDG in the lactating breast. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  U. Cremerius,et al.  Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma , 2001, Nuklearmedizin.

[35]  C. Meltzer,et al.  Superphysiologic FDG Uptake in the Non-Paralyzed Vocal Cord. Resolution of a False-Positive PET Result with Combined PET-CT Imaging. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[36]  Michael N. Maisey,et al.  Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine , 1999, European Journal of Nuclear Medicine.

[37]  H. Herzog,et al.  Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer , 1999, European Journal of Nuclear Medicine.

[38]  R L Wahl,et al.  Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.

[39]  S. Yasuda,et al.  Lactating breast exhibiting high F-18 FDG uptake. , 1998, Clinical nuclear medicine.

[40]  A. Ezzat,et al.  F-18-FDG uptake in tuberculosis. , 1998, Clinical nuclear medicine.

[41]  D Delbeke,et al.  Prospective investigation of positron emission tomography in lung nodules. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Barrington,et al.  Speech-related visualization of laryngeal muscles with fluorine-18-FDG. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  A. Civelek,et al.  Bone scintigraphy of caudal regression syndrome. , 1996, Clinical nuclear medicine.

[44]  I. Fogelman,et al.  Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. , 1996, Seminars in nuclear medicine.

[45]  A. Buck,et al.  Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  R. Wahl.  Targeting glucose transporters for tumor imaging: "sweet" idea, "sour" result. , 1979, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  J. Keyes.  SUV: standard uptake or silly useless value? , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  K. McGowan,et al.  Glucose transporter gene expression: regulation of transcription and mRNA stability. , 1995, Pharmacology & therapeutics.

[49]  L M Hamberg,et al.  The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  S. Cherry,et al.  Physics in Nuclear Medicine , 2004 .

[51]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[52]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.